This biotech growth stock has soared in the coronavirus pandemic. Here’s what you need to know

Here are two potential growth stocks, affected by Covid-19 in different ways. Their share prices have headed in opposite directions in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I’ve had Oxford Biomedica (LSE: OXB) on my watchlist for some time now. By 2018, it had achieved a key milestone for a biotechnology growth stock — it recorded a profit. But early investor enthusiasm waned, and since a peak that year, the Oxford Biomedica share price has fallen back by around 20%.

The initial profitability has not been repeated yet, and 2019 saw a return to loss and cash burn. The firm needed further funding, raising £40m from a placing as recently as June 2020.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Forecasts suggest a further, albeit smaller, loss for the current year. But the Covid-19 pandemic has given the shares a new lease of life. They’re up 30% so far in 2020, after an initial sharp dip when the crisis first struck.

New growth stock phase?

Oxford Biomedica bills itself as “a leading gene and cell therapy group” and it partners with such pharmaceutical giants as AstraZeneca. AZN is big on Covid-19 research, with its vaccine trial currently in the news. So that’s where the tie-up for Oxford Biomedica comes in, and its technology could make it a serious long-term growth stock.

The first half of the year saw Oxford Biomedica’s revenue grow by 6% to £34m. And key sources of income like licences and royalties are rising. But it’s still ploughing lots of cash into R&D, with operating expenses up 41% in the period.

In the early days, when a growth stock turns to profit, it can often pay to wait until that profitability is sustainable. Forecasts suggest a 2021 profit for Oxford Biomedica. And with revenue growing strongly, I can see further earnings growth ahead. If that happens, 2020 could turn out to be a great time to buy.

Health recovery?

Spire Healthcare (LSE: SPI), meanwhile, has been having a terrible time. The hospital group was previously seen as a growth stock, based on its cancer care specialism. But after three years of falling earnings, the dividend has been slashed and the share price has crashed.

Since the start of 2020, Spire Healthcare shares are down 33%. Over the past five years, we’re looking at a 75% fall. And analysts are forecasting a loss for the current year. But they have a return to profit pencilled in for 2021 — and they’re even predicting a return to dividend growth.

Headline figures for the first half don’t look great. Revenue fell 18.2%, and Spire recorded a pre-tax loss of £231.3m. But that includes a chunk of one-offs, and the company puts adjusted EBITDA at a positive £61.6m.

Outlook

The balance sheet looks comfortable enough, with net bank debt improving by 8.7% to £330.6m. But what’s the outlook like?

The company said: “There has been a return of private activity since lockdown and there is significant national unmet demand for both private and NHS procedures. Subject to any significant change in the Covid environment, the board anticipates trading returning to 2019 levels in 2021.

If that’s the start of a new earnings growth phase, we could be looking at two long-term growth stocks here.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

3 reasons why the stock market is falling today

Jon Smith explains several factors that are contributing to the stock market falling today, and his thoughts on them.

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

2 stocks that are great long-term picks

As recession fears weigh on share prices, our author has found two stocks with strong long-term prospects. He’s looking at…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

2 lesser-known penny stocks to buy now and hold for 10 years!

I’m currently looking at penny stocks that could help my portfolio grow over the next 10 years. Despite recent volatility,…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

Here’s 1 of the best stocks to buy for passive income

Jabran Khan delves deeper into one of the best stocks to buy for passive income, which is a FTSE 100…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

IAG shares are down 15% amid travel chaos! Is now the time to buy?

IAG shares have collapsed over the past month. Shareholders had hoped for a strong Q2. But maybe this represents a…

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

UK shares: 1 dividend stock I own to combat inflation

This Fool is looking for quality UK shares to combat inflation through consistent and stable returns as well as growth…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how I’m investing as stock market volatility soars!

2022 has seen an explosion in stock market volatility. But with the right approach I think ongoing choppiness could turbocharge…

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

2 top FTSE 100 shares to buy before a new bull market

On my search for FTSE 100 shares to buy before the recovery, I have found two growth options that could…

Read more »